SEC Form 4
BridgeBio Pharma, Inc. (BBIO) insider trading
In the 12 months to Nov 19, 2026, 8 BBIO insiders reported open-market sales of $93.5M across 33 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $93.5M
- 33 filings · 8 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 32 of 33
- $87.2M of $93.5M sold (93%)
Who traded BBIO, and when
- Sale
- Sale, pre-arranged (10b5-1)
BBIO daily close from Nov 19, 2025 to Nov 18, 2026, between $63.30 and $90.17, last $78.01. 33 sale and 0 purchase filings by 8 insiders, marked at their filing dates. Neil Kumar, Chief Executive Officer: sold $52.2M across 13 filings, first filed Nov 24, 2025, last Sep 21, 2026. Jennifer E. Cook, Director: sold $21.9M across 3 filings, first filed Jun 17, 2026, last Jul 13, 2026. Andrew Lo, Director: sold $6.3M across 1 filing, first filed Nov 19, 2025, last Nov 19, 2025. Andrea Ellis, Director: sold $5.7M across 2 filings, first filed Mar 6, 2026, last Jul 13, 2026. Hannah Valantine, Director: sold $2.7M across 3 filings, first filed Mar 3, 2026, last Jun 24, 2026. Randal W. Scott, Director: sold $2.1M across 3 filings, first filed Nov 19, 2025, last May 19, 2026. 2 others: sold $2.7M across 8 filings, first filed Dec 10, 2025, last Nov 3, 2026.
Largest mark · tap a row for others
Jennifer E. Cook · Director
Sale $13,156,008
148,589 shares at $88.54 avg
Filed Jul 13, 2026 · traded Jul 9
Pre-arranged (10b5-1) · close on filing date $83.08
Neil Kumar · Chief Executive Officer
Chief Executive Officer
$52.2M soldJennifer E. Cook · Director
Director
$21.9M soldAndrew Lo · Director
Director
$6.3M soldAndrea Ellis · Director
Director
$5.7M soldHannah Valantine · Director
Director
$2.7M soldRandal W. Scott · Director
Director
$2.1M sold2 others
Combined, one mark per week
$2.7M soldOpen-market trades
33 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Neil Kumar | Chief Executive Officer | $52.2M | — | 13 | 100% of sales | |
| Jennifer E. Cook | Director | $21.9M | — | 3 | 100% of sales | |
| Andrew Lo | Director | $6.3M | — | 1 | — | |
| Andrea Ellis | Director | $5.7M | — | 2 | 100% of sales | |
| Hannah Valantine | Director | $2.7M | — | 3 | 100% of sales | |
| Randal W. Scott | Director | $2.1M | — | 3 | 100% of sales | |
| Thomas Trimarchi | President and CFO | $1.9M | — | 2 | 100% of sales | |
| Maricel Apuli | Chief Accounting Officer | $767.4K | — | 6 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Maricel Apuli Chief Accounting Officer | SalePre-arranged (10b5-1) | 2,000 | $72.85 | $145.7K | 120,687 | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 10,000 | $69.08 | $690.8K | 495,686 | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 44,980 | $82.86 | $3.7M | Multiple accounts | |
traded | Maricel Apuli Chief Accounting Officer | SalePre-arranged (10b5-1) | 2,000 | $80.06 | $160.1K | 127,401 | |
traded | Jennifer E. Cook Director | SalePre-arranged (10b5-1) | 148,589 | $88.54 | $13.2M | 120,805 | |
traded | Andrea Ellis Director | SalePre-arranged (10b5-1) | 17,167 | $84.00 | $1.4M | 22,579 | |
traded | Hannah Valantine Director | SalePre-arranged (10b5-1) | 5,004 | $68.25 | $341.5K | 9,259 | |
traded | Jennifer E. Cook Director | SalePre-arranged (10b5-1) | 39,363 | $69.92 | $2.8M | 8,383 | |
traded | Jennifer E. Cook Director | SalePre-arranged (10b5-1) | 90,240 | $66.62 | $6.0M | 6,589 | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 80,000 | $67.67 | $5.4M | Multiple accounts | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 26,103 | $69.44 | $1.8M | 267,174 | |
traded | Randal W. Scott Director | SalePre-arranged (10b5-1) | 10,000 | $67.15 | $671.5K | 11,589 | |
traded | Thomas Trimarchi President and CFO | SalePre-arranged (10b5-1) | 13,651 | $65.08 | $888.4K | 362,389 | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 80,000 | $67.40 | $5.4M | Multiple accounts | |
traded | Maricel Apuli Chief Accounting Officer | SalePre-arranged (10b5-1) | 2,000 | $71.58 | $143.2K | 134,115 | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 80,000 | $74.61 | $6.0M | Multiple accounts | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 80,000 | $68.76 | $5.5M | Multiple accounts | |
traded | Hannah Valantine Director | SalePre-arranged (10b5-1) | 8,671 | $72.00 | $624.3K | 7,465 | |
traded | Andrea Ellis Director | SalePre-arranged (10b5-1) | 64,921 | $64.87 | $4.2M | 18,589 | |
traded | Hannah Valantine Director | SalePre-arranged (10b5-1) | 25,484 | $67.41 | $1.7M | 7,465 | |
traded | Maricel Apuli Chief Accounting Officer | SalePre-arranged (10b5-1) | 2,000 | $66.00 | $132.0K | 121,945 | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 28,053 | $71.39 | $2.0M | 235,053 | |
traded | Randal W. Scott Director | SalePre-arranged (10b5-1) | 10,000 | $75.46 | $754.6K | 11,589 | |
traded | Thomas Trimarchi President and CFO | SalePre-arranged (10b5-1) | 13,600 | $74.72 | $1.0M | 336,785 | |
traded | Maricel Apuli Chief Accounting Officer | SalePre-arranged (10b5-1) | 510 | $74.31 | $37.9K | 123,945 | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 80,000 | $71.86 | $5.7M | Multiple accounts | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 80,000 | $75.54 | $6.0M | Multiple accounts | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 30,011 | $74.64 | $2.2M | 228,776 | |
traded | Maricel Apuli Chief Accounting Officer | SalePre-arranged (10b5-1) | 2,000 | $74.26 | $148.5K | 130,297 | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 80,000 | $73.86 | $5.9M | Multiple accounts | |
traded | Neil Kumar Chief Executive Officer | SalePre-arranged (10b5-1) | 26,156 | $65.84 | $1.7M | 228,776 | |
traded | Randal W. Scott Director | SalePre-arranged (10b5-1) | 10,000 | $66.65 | $666.5K | 17,788 | |
traded | Andrew Lo Director | Sale | 95,599 | $66.11 | $6.3M | Multiple accounts |
GET /stocks/filings/vX/form-4?tickers=BBIO&filing_date.gte=2025-11-19&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"BBIO"
],
"issuer_cik": "0001743881",
"owner_cik": "0002058197",
"accession_number": "0001470831-26-000976",
"form_type": "4",
"filing_date": "2026-11-03",
"period_of_report": "2026-10-30",
"issuer_name": "BridgeBio Pharma, Inc.",
"issuer_trading_symbol": "BBIO",
"owner_name": "Apuli Maricel",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Accounting Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-30",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 2000,
"transaction_price_per_share": 72.85,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 120687,
"transaction_value": 145700,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025."
}
]
},
{
"tickers": [
"BBIO"
],
"issuer_cik": "0001743881",
"owner_cik": "0001742485",
"accession_number": "0001470831-26-000897",
"form_type": "4",
"filing_date": "2026-09-21",
"period_of_report": "2026-09-17",
"issuer_name": "BridgeBio Pharma, Inc.",
"issuer_trading_symbol": "BBIO",
"owner_name": "Kumar Neil",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-17",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 8721,
"transaction_price_per_share": 69.0136,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 496965,
"transaction_value": 601867.6056,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.",
"footnotes": [
{
"id": "F1",
"description": "This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."
},
{
"id": "F2",
"description": "Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."
},
{
"id": "F3",
"description": "The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 61 records
- Option exercises31 records
- Tax withholding16 records
- Grants and awards14 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has BridgeBio Pharma, Inc.'s CEO sold stock?
Yes. Neil Kumar (CEO) sold 725,303 shares ($52.2M) between Nov 2025 and Sep 2026, all under a pre-arranged 10b5-1 plan.
How current is BBIO’s insider data?
These are BBIO Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track BBIO insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for BBIO every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.